MabVax Stockholders Approve Proposals at Special Meeting of Stockholders

December 1, 2017

Responsive image

SAN DIEGO, Dec. 1, 2017 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that its stockholders approved a…

Category: Precious Metals